Hudi Hastowo

Badan Tenaga Nuklir Nasional-BATAN 5 November 2009

Role of BATAN in Establishing Nuclear Oncology in Indonesia

BATAN has the following functions :

l To assess and prepare the national policy in the field of research, development, and the beneficial uses of nuclear energy:

l Food, energy, health, etc

l To support and foster activities of government institutions in the field of research, development and beneficial uses of nuclear energy,

l Liaison officer to the international institution dealing with nuclear activities: IAEA, FNCA, others

l Cancer kills 7 million people each year l 25 million live with cancer; over 10 million new cases this

year, more than half in developing countries and increasingl By 2020, cancer could kill over 10 million, while new cases

could rise to 16 million per year unless we actl Radiation and nuclear oncology is an essential and integral

component of cancer carel In spite of assistance programs, developing countries not

able to deal with this epidemic todayl More than 2 million lives can be saved by 2020 if

appropriate measures are put in place to prevent, detect early, diagnose, and cure

The Burden of Cancer

Massoud Samiei, IAEA

l Program of Action for Cancer Therapy (PACT) is the IAEA’s response to the cancer challenge in developing countries

• The long-term objective of PACT is:

PACT: IAEA’s Response …

Sustainable National Capacity for Cancer Care

l Build sustainable national cancer care infrastructure and capacity towards eventual self-sufficiency through South-South and North-South partnerships

l Systematically plan and build capacity to diagnose and treat all patients with radiosensitive cancers

l Focus on eliminating all cancer morbidity and mortality from unmet treatment needs among patients for whom radiotherapy is most effective

l Deploy consistent and predictable resources and processes including investments from private donors to meet these objectives over a 5 to 10 year strategy

The Vision for PACT

Massoud Samiei, IAEA

PACT is being operationalised using specific mechanisms such as imPACT (integrated missions of PACT)

l Assist governments to review, analyse and formulate National Cancer Strategies and Action Plans for capacity building from prevention through palliation

l Enable institutions to build and develop human resources and plans for capacity in radiation and nuclear oncology

The imPACT Review will:

The results of imPACT will enable governments to:

l Work with partnersl Focus on centres of competence/reference to deliver

quality cancer carel Raise public awareness of cancer prevention,

diagnosis, and therapyl Apply best practices, expand and continue

professional developmentMassoud Samiei, IAEA

IAEA Ministry of Research & Technology

Ministry of Health

DG of Medical Care, Ministry of Health

DG of Disease Control & Environmental Health,

Ministry of Health

National Nuclear Energy Agency

(BATAN)

Dharmais Cancer Hospital, National Cancer Center

National Cancer Control Program• Prevention• Early detection • Diagnosis• Treatment

PACT• Cancer Diagnosis• Cancer Treatment

PACT Fundamentals• National Cancer Control Programs:

• Radiation Medicine and the role of the BATAN and the IAEA

Ø PreventionØ Early DetectionØ Diagnosis and TreatmentØ Palliative Care

* Radiation Medicine includes both radiotherapy (or radiation oncology) and diagnostic imaging involving the safe use of ionizing radiation and nuclear medicine procedures.

BATAN’s Role for PACT/Nuclear Oncology:

• Carry out R&D on radiopharmaceuticals, RIA/IRMA Kits, and brachytherapy sealed sources for PACT

• Encourage national companies, such as PT Kimia Farma, PT Batan Technology to produce and distribute products for PACT developed by BATAN

• Provide services to nuclear instruments associated with PACT

Radiopharmaceuticals developed by BATAN for Nuclear Oncology:l PET and SPECT radiopharmaceuticals, such as 18FDG,

18FLT, 123I-MIBG, 99mTc-HYNIC Octreotide, 99mTc-HYNIC-Folate, etc.

l Therapeutic radiopharmaceuticals:

l PZC-Based 188W/188Re Therapeutic Generator

- 153Sm-EDTMP- 186Re-HEDP- 131I-MIBG - 131I-Lipiodol - 177Lu-DOTA-Nimotuzumab- 177Lu-DOTA-Trastuzumab Radioimmunotherapy

RIA Kits developed by BATAN for Nuclear Oncology:

• IRMA Kit CA 125 for in vitro diagnosis of ovarium cancer

• IRMA Kit CA 15.3 for in vitro diagnosis of breast cancer

Sealed Sources developed by BATAN for Nuclear Oncology:

l125I Seed sealed sources for seed brachytherapy of prostate cancer

l192Ir needle sealed sources for HDR/LDR brachytherapyfor cervics cancer, etc.

BATAN’s Facility for Producing Radionuclide of 125I

BATAN’s Laser Welder for preparing 125I seed and 192Ir needle sealed-sources

125I seed sealed-sources

Brachytherapy of Prostate Cancer using 125I seeds

Program Action BATAN’s Contribution

• Early Detection• Develop RIA/IRMA Kits, PET and

SPECT radiopharmaceuticals as required by Hospitals involved in PACT

• Diagnosis • Develop PET and SPECT radiopharmaceuticals as required by Hospitals involved in PACT

• Treatment or Therapy

• Develop sealed sources (needle, seed)for HDR and LDR Brachytherapy, CND Brachytherapy, Targeted Therapeutic Radiopharmaceuticals

• Palliative Care • Develop simple and targeted therapeutic radiopharmaceuticals

Summary

• BATAN will actively involve to support PACT through the R&D programs in the health field.

• BATAN will encourage a close relationship and communication between BATAN’s Centers with hospitals/medical doctors to develop radiopharmaceuticals/RIA and IRMA Kits, sealed sources for brachytherapy suitable for local condition.

THANK YOU